Mosby's 2014 Nursing Drug Reference (59 page)

BOOK: Mosby's 2014 Nursing Drug Reference
10.91Mb size Format: txt, pdf, ePub
ads

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

belatacept

(bel-a-ta′sept)

Nulojix

Func. class.:
Biologic response modifier

Chem. class.:
Fusion protein

ACTION:

Activated T lymphocytes are the mediators of immunologic rejection, this product is a selective T-cell costimulation blocker; blocks the CD28 mediated costimulation of T lymphocytes by binding to CD80 and CD86 on antigen-presenting cells; inhibits T lymphocyte proliferation and the production of the cytokines interleukin-2, interferon-gamma, interleukin-4, and TNF-alpha.

USES:

Kidney transplant rejection prophylaxis given with basiliximab induction, mycophenolate mofetil, corticosteroids

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Breastfeeding, child/infant/neonate, pregnancy (C), diabetes mellitus, progressive multifocal leukoencephalopathy, immunosuppression, sunlight exposure, TB

 

Black Box Warning:

Infection, organ transplant, requires an experienced clinician, secondary malignancy, posttransplant lymphoproliferation disorder

DOSAGE AND ROUTES
Calculator

• Adult: IV
10 mg/kg rounded to the nearest 12.5 mg increment; give over 30 min the day of transplantation (day 1) but before transplantation, on day 5 approximately 96 hours after the day 1 dose 1, at the end of wk 2, at the end of wk 4, at the end of wk 8, and at the end of wk 12; maintenance dosage is 5 mg/kg rounded to the nearest 12.5 mg increment; give over 30 min at the end of wk 16 and every 4 wk ± 3 days thereafter; doses should be calculated on actual body weight on the transplantation day unless the patient’s weight varies by >10%

Available forms:
Powder for inj 250 mg

Administer:

 

Black Box Warning:

Only providers skilled in the use of immunosuppressant and management of transplant should use these products

IV route

• 
Visually inspect product for particulate matter, discoloration whenever sol/container permit, discard if present

• 
Calculate the number of drug vials required to provide total inf dose

• 
Reconstitute each vial/10.5 ml of sterile water for injection, 0.9% sodium chloride, D
5
W, using the silicone-free disposable syringe provided with each vial and an 18-21G needle. If silicone-free disposable syringe is dropped or becomes contaminated, use a new silicone-free disposable syringe from inventory. If you need additional silicone-free disposable syringes, call 1-888-685-6549. If the powder is accidentally reconstituted using a different syringe than the one provided, the sol may develop a few translucent particles. Discard any sol prepared using siliconized syringes.

• 
Using aseptic technique, inject the diluent into the vial and direct the stream of diluent to the glass wall of the vial; to minimize foaming, rotate the vial and invert with gentle swirling until the contents are dissolved; do not shake when reconstituted (25 mg/ml), should be clear to slightly opalescent and colorless to pale yellow; do not use if opaque particles, discoloration, or other foreign particles are present.

• 
Calculate the total volume of the reconstituted 25 mg/ml sol required to provide the total inf dose; further dilute this volume with a volume of inf fluid equal to
the volume of the reconstituted drug sol required to provide the prescribed dose. Use either NS or D
5
W if drug was reconstituted with SWFI; use NS if drug was reconstituted with NS; use D
5
W if drug was reconstituted with D
5
W. With the same silicone-free disposable syringe used for reconstitution, withdraw the required amount of belatacept sol from the vial, inject it into the inf container, gently rotate the inf container to ensure mixing; final conc in inf container should range (2-10 mg/ml). Volume of 100 ml will be appropriate for most patients and doses, but total inf volumes ranging from 50-250 ml may be used. Discard any unused drug sol remaining in the vials; after reconstitution, immediately transfer the reconstituted sol from the vial to the inf bag or bottle; complete within 24 hr.

IV INF route

• 
Give over 30 min, use an inf set and a sterile, nonpyrogenic, low-protein-binding filter (0.2-1.2 mm), use a separate line

SIDE EFFECTS

CNS:
Guillain-Barré syndrome, anxiety, dizziness, headache, fever, insomnia, tremor

EENT:
Pharyngitis, stomatitis

GI:
Abdominal pain, constipation, diarrhea, nausea, vomiting

GU:
Renal tubular necrosis, renal failure,
proteinuria, urinary incontinence

HEMA:
Anemia, neutropenia, leucopenia, leukoencephalopathy

INTEG:
Acne, alopecia

META:
Hypercholesterolemia, hyperglycemia, hyper/hypokalemia, hypocalcemia, hypophosphatemia, hypomagnesemia

MS:
Arthralgia

SYST:
Secondary malignancy, posttransplant lymphoproliferation disorder, wound dehiscence, BK-virus-associated neuropathy

PHARMACOKINETICS

Half-life, 6.1-15.1 days during receipt of 10 mg/kg IV doses; during receipt of 5 mg/kg IV doses, terminal half-life 3.1-11.9; steady-state by wk 8 after transplantation and by month 6 during maintenance phase

INTERACTIONS

Increase:
Basiliximab induction, mycophenolate mofetil

NURSING CONSIDERATIONS
Assess:

 

Black Box Warning:

Transplant rejection: flulike symptoms, decreasing urinary output, malaise; some may experience pain in area (rare; monitor BUN/creatinine)

 

Black Box Warning:

Infection: monitor for fever, chills, increased WBC,
wound dehiscences

 

Black Box Warning:

Posttransplant lymphoproliferation disorder: may lead to secondary malignancy (lymphoma) or infectious mononucleosis-like lesions; may be treated with antivirals or immunosuppressant; product may need to be discontinued

• 
Hyperlipidemia: monitor cholesterol, triglycerides; an antilipidemic may be needed

Perform/provide:

• 
Storage: refrigerated, protected from light ≤24 hr; max 4 hr of the total 24 hr can be at room temp and room light

Evaluate:

• 
Therapeutic response: absence of renal transplant rejection

Teach patient/family:

• 
Reason for product and expected result

• 
To avoid exposure to sunlight, tanning beds, risk of secondary malignancy

• 
To avoid crowds, persons with known infections

• 
That repeated lab test will be needed

• 
To avoid with vaccines

• 
That immunosuppressants will be needed for life to prevent rejection; teach symptoms of rejection and to call provider immediately

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

belimumab

(be-lim′ue-mab)

Benlysta

Func. class.:
Monoclonal antibody

Chem. class.:
Disease-Modifying Antirheumatic Drugs (DMARDs)

ACTION:

Inhibits B lymphocyte stimulator (BLyS), needed for B-cell survival; normally, soluble BLyS binds to its receptors on B cells and allows B-cell survival; binds BLyS and prevents binding to its receptors on B-cells

USES:

Active, autoantibody-positive, systemic lupus erythematosus (SLE) in combination with standard therapy

CONTRAINDICATIONS:

Hypersensitivity

Precautions:
Pregnancy (C), breastfeeding, children/infants, geriatric patients, African decent patients, depression, immunosuppression, infection, suicidal ideation, vaccination, secondary malignancy, cardiac disease; requires experienced clinician

DOSAGE AND ROUTES
Calculator

• Adult: IV
10 mg/kg over 1 hr q2wk for the first 3 doses then q4wk

Available forms:
Powder for injection 120, 400 mg

Administer:

• 
Only health care providers prepared to manage anaphylaxis should administer this product; may give premedication for prophylaxis against infusion and hypersensitivity reactions

Intermittent IV INF route

• 
Visually inspect particulate matter and discoloration whenever sol and container permits

• 
Give as IV inf only, do not give IV bolus or push; give over 1 hr and slow or stop if inf reactions occur

• 
Do not give with any other agents in the same IV line

• 
Allow to stand at room temp for 10-15 min before using

• 
Reconstitute with the appropriate amount of sterile water for injection (80 mg/ml); add 1.5 ml of sterile water (120 mg/vial) or 4.8 ml of sterile water (400 mg/vial)

• 
Direct the stream of sterile water toward the side of the vial to minimize foaming; gently swirl for 60 sec, allow to sit during reconstitution, gently swirl for 60 sec q5min until the powder is dissolved; do not shake; reconstitution is complete in 10 to 30 min

• 
If a mechanical reconstitution device (swirler) is used, max 500 rpm swirled for ≤30 min.

• 
Sol should be opalescent and colorless to pale yellow and without particles; small air bubbles are expected; protect from sunlight

• 
Dilution: only dilute in normal saline for injection; dilute reconstituted sol with enough normal saline to 250 ml. From a 250-ml inf bag or bottle of normal saline, withdraw and discard a volume equal to the volume of the reconstituted sol required for dose; add the required volume of the reconstituted sol the infusion bag/bottle; gently invert to mix

• 
Discard any unused sol

SIDE EFFECTS

CNS:
Headache, dizziness, anxiety, depression, fever, insomnia, migraine,
suicidal ideation

CV:
Bradycardia, hypotension

GI:
Nausea, diarrhea

MISC:
Rash, dyspnea, cystitis, leukopenia, myalgia, rash, bronchitis, nasopharyngitis, pharyngitis

SYST:
Anaphylaxis, angioedema, antibody formation, secondary malignancy, infection, influenza

PHARMACOKINETICS

Terminal half-life 19.4 days; distribution half-life 1.75 days

NURSING CONSIDERATIONS
Assess:

• 
SLE:
monitor for decreasing fever, malaise, fatigue, joint pain, myalgias

• 
Suicidal ideation:
more common in those with preexisting depression

• 
Infection:
determine if a chronic or acute infection is present, may be fatal when used with this product; do not begin therapy if any products are being used for a chronic infection; leucopenia may occur with this product and susceptibility to infections increased

• 
Anaphylaxis,
infusion site reactions: if these occur, stop infusion

• 
African descent patients:
use cautiously in these patients, may not respond to this product

• 
Cardiac disease: monitor closely for cardiovascular side effects, bradycardia, hypotension


 
Pregnancy: determine if pregnant or if pregnancy is planned or suspected; if pregnant, call 1-877-681-6269 to enroll in registry

Perform/provide:

• 
Storage in refrigerator or at room temp; total time from reconstitution to completion of inf max 8 hr

Evaluate:

• 
Positive response: Decreasing symptoms of SLE: decreasing fatigue, fever, malaise

Teach patient/family:


 
To notify prescriber if pregnancy is planned or suspected, to use reliable contraception during and for 4 months after final treatment; to avoid breastfeeding

• 
To seek treatment immediately for serious hypersensitive reactions

• 
Not to receive vaccinations during treatment

BOOK: Mosby's 2014 Nursing Drug Reference
10.91Mb size Format: txt, pdf, ePub
ads

Other books

The Stoned Apocalypse by Marco Vassi
Together With You by Victoria Bylin
Played to Death by Meg Perry
Silent Deception by Cathie Dunn
Expecting to Fly by Cathy Hopkins
Outlaw's Bride by Lori Copeland
Washington Square by Henry James